Atherosclerosis in 2010: New therapeutic insights

Nature Reviews Cardiology

Volumn 8, Issue 2, 2011, Pages 70-72

  Nissen, Steven E ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANACETRAPIB; CHOLESTEROL ESTER TRANSFER PROTEIN; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; PLACEBO; SIMVASTATIN; TORCETRAPIB;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL RESEARCH; COMBINATION CHEMOTHERAPY; DIALYSIS; DRUG SAFETY; HUMAN; KIDNEY FAILURE; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

ATHEROSCLEROSIS; DATA COLLECTION; HUMANS;

EID: 79251638899     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2010.208     Document Type: Review

References (10)

1. ACCOrD Study Group. effects of combination ipid therapy in type 2 diabetes mellitus. N. Engl. J. Med. 362, 1563-1574 (2010).
2. Cannon, C. P et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N. Engl. J. Med. doi:10.1056/neJMoa1009744.
3. Sharp Collaborative Group. Study of Heart and renal Protection (SHarP): randomized trial to assess the effects of lowering low-density ipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am. Heart J. 160, 785-794 (2010).
4. Frick, M. H. et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med. 317, 1237-1245 (1987).
5. Rubins, H. B. et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density ipoprotein cholesterol. N. Engl. J. Med. 341, 410-418 (1999).
6. Keech, A. et al. effects of long-term fenofibrate therapy on cardiovascular events in 9,795 people with type 2 diabetes mellitus (the FieLD study): randomised controlled trial. Lancet 366, 1849-1861 (2005).
7. Brousseau, M. E. et al. effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N. Engl. J. Med. 350, 1505-1515 (2004).
8. Hirano, K. et al. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity Arterioscler. Thromb. Vasc. Biol. 17, 1053-1059 (1997).
9. Barter, P J. et al. effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357, 2109-2122 (2007).
10. Baigent, C. & Landry, M. Study of Heart and renal Protection (SHarP). Kidney Int. Suppl. 84, S207-S210 (2003).